

Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years

NCT06993636

Status	RECRUITING
Sponsor	Children's Hospital of Fudan University
Enrollment	60 participants

Key Eligibility Criteria

Inclusion (3)

- Giant coronary artery aneurysm(s) in any coronary artery after acute stage of Kawasaki disease. Giant coronary artery aneurysm(s) should be confirmed by two-dimensional echocardiography and meet the diagnostic criteria of Z-score ≤ 10 or coronary artery internal diameter ≥ 8 mm;
- Anticoagulant with antiplatelet drug therapy for anti-thromboprophylaxis is recommended for the next 6 months;
- Children aged 2 years to <18 years

Exclusion (3)

- Active bleeding or bleeding risk contraindicating anticoagulant therapy
- Hypersensitivity or any other contraindications listed in the local labeling for the comparator treatment or experimental treatment
- Patients participating in clinical trials of other drugs at the same time

Locations (1 total)

Children's Hospital of Fudan University, Shanghai, Shanghai Municipality, China